As of 2024-12-11, the EV/EBITDA ratio of Relay Therapeutics Inc (RLAY) is -1.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RLAY's latest enterprise value is 681.20 mil USD. RLAY's TTM EBITDA according to its financial statements is -654.99 mil USD. Dividing these 2 quantities gives us the above RLAY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.4x | 16.0x |
| Forward P/E multiples | 15.7x - 21.4x | 15.8x |
| Fair Price | (60.68) - (67.10) | (61.31) |
| Upside | -1318.5% - -1447.4% | -1331.1% |
| Date | EV/EBITDA |
| 2024-12-02 | -0.95 |
| 2024-11-29 | -0.97 |
| 2024-11-27 | -0.99 |
| 2024-11-26 | -0.98 |
| 2024-11-25 | -1.01 |
| 2024-11-22 | -0.98 |
| 2024-11-21 | -0.95 |
| 2024-11-20 | -0.96 |
| 2024-11-19 | -0.99 |
| 2024-11-18 | -1.02 |
| 2024-11-15 | -1.07 |
| 2024-11-14 | -1.20 |
| 2024-11-13 | -1.25 |
| 2024-11-12 | -1.29 |
| 2024-11-11 | -1.34 |
| 2024-11-08 | -1.35 |
| 2024-11-07 | -1.34 |
| 2024-11-06 | -1.36 |
| 2024-11-05 | -1.29 |
| 2024-11-04 | -1.26 |
| 2024-11-01 | -1.26 |
| 2024-10-31 | -1.21 |
| 2024-10-30 | -1.23 |
| 2024-10-29 | -1.28 |
| 2024-10-28 | -1.31 |
| 2024-10-25 | -1.31 |
| 2024-10-24 | -1.35 |
| 2024-10-23 | -1.38 |
| 2024-10-22 | -1.47 |
| 2024-10-21 | -1.41 |
| 2024-10-18 | -1.49 |
| 2024-10-17 | -1.46 |
| 2024-10-16 | -1.51 |
| 2024-10-15 | -1.49 |
| 2024-10-14 | -1.49 |
| 2024-10-11 | -1.51 |
| 2024-10-10 | -1.45 |
| 2024-10-09 | -1.41 |
| 2024-10-08 | -1.36 |
| 2024-10-07 | -1.39 |
| 2024-10-04 | -1.44 |
| 2024-10-03 | -1.43 |
| 2024-10-02 | -1.43 |
| 2024-10-01 | -1.44 |
| 2024-09-30 | -1.58 |
| 2024-09-27 | -1.67 |
| 2024-09-26 | -1.66 |
| 2024-09-25 | -1.57 |
| 2024-09-24 | -1.63 |
| 2024-09-23 | -1.67 |